Iambic Therapeutics
Iambic Therapeutics is a biotech company that uses AI to design differentiated drug candidates, with a clinical pipeline targeting HER2, KIF18A, and CDK2/4.

Medable is a clinical trial platform that unifies eCOA, eConsent, sensors, and device data with a purpose-built AI agent platform for GxP-compliant trial operations.
Medable is a clinical trial platform for sponsors, sites, and clinical operations teams that combines eCOA, eConsent, sensors, provisioned devices, and BYOD into a unified experience, with a purpose-built AI agent platform for clinical development.
Medable's Agent Platform is designed specifically for clinical development, with deep context across GxP compliance, regulatory requirements, and the operational complexity that general-purpose AI platforms are not equipped to navigate. The platform aims to unify clinical systems and workflows, turning data into intelligent, trusted action while reducing manual burden across clinical operations. This is not a generic AI layer applied to trials; it is built for the regulatory and operational realities of clinical research.
Medable's agentified eCOA brings AI-powered workflows to every stage of the trial, from build and deployment to study conduct and data review. The goal is consistent, high-quality data and stronger participant adherence. The platform spans eConsent, sensors, provisioned devices, and BYOD, offering a unified experience that reduces operational complexity across every touchpoint of the trial. By connecting these elements, Medable aims to streamline the participant journey and the data flow from source to review.
Medable reports several clinical outcomes backed by real-world evidence. eCOA participant adherence exceeded 90% across a 70+ site master protocol, with near-perfect compliance. In Japan, eCOA adherence reached 99%, and first patient in (FPI) was achieved ahead of schedule across a complex regional rollout. Medable Studio reduced trial build time from weeks to one business day. AI-powered translation cut translation timelines by 43%, or half the time to go-live. These figures are company-reported and may vary by study.
Medable positions its AI as autonomous where it can be and human-led where it must be, with clinical judgment amplified rather than replaced. Every automated action is logged, explainable, and auditable end-to-end. Critical decisions stay with the study team through human-in-the-loop controls, giving teams full control. Regulatory context is built in from day one, not retrofitted after. This approach supports the traceability and oversight that GxP environments require.
Medable states that it is built for global regulatory compliance and data integrity, with alignment to HIPAA, GDPR, ISO, FDA 21 CFR Part 11, and ICH E6(R2) GCP. These frameworks matter for sponsors running trials across regions, where data integrity and audit readiness are non-negotiable. The platform's compliance posture is a core part of its value proposition for regulated clinical research.
Medable describes a 1:1:1 vision: one day study start, one day patient enrollment, one year study conduct. The company calls this an ambitious vision and one it is actively building toward. With agentic AI purpose-built for clinical development, Medable says it is making meaningful progress toward timelines the industry once thought were out of reach. This vision is aspirational and not a current guarantee.
Medable's strengths lie in its clinical-specific design, human-in-the-loop controls, and unified data experience. The reported adherence and build-time improvements are notable, though they come from Medable's own evidence and may not generalize to every trial. Pricing is not publicly disclosed, so interested teams should book a demo to learn more. The 1:1:1 vision is a long-term goal, not a current capability. For sponsors and sites evaluating AI in clinical trials, Medable offers a purpose-built option that prioritizes traceability and regulatory context.
Subscription pricing is not listed.
Features, pricing and availability may change. Always verify details on the official website. Maintained by steven · Last updated Oct 16, 2026 →
Iambic Therapeutics is a biotech company that uses AI to design differentiated drug candidates, with a clinical pipeline targeting HER2, KIF18A, and CDK2/4.
Microsoft for Healthcare brings Dragon Copilot, Dragon Medical One, and PowerMic Mobile to clinicians, combining speech recognition and an AI clinical assistant to streamline documentation and clinical tasks.
Notable is a healthcare automation platform that deploys AI agents across patient access, revenue cycle, care operations, and contact center work. It is built for health systems, health plans, and provider organizations that want to reduce administrative load without adding staff.
IQVIA provides life sciences organizations with data, analytics, and technology to accelerate innovation, improve patient outcomes, and bring treatments to market faster.